GlycoDesign and Leo in cardiovascular deal

Under a three-year collaboration, GlycoDesign (Toronto, Ontario) and Leo (Ballerup, Denmark) will develop three glycosaminoglycan (GAG)-based compounds to treat cardiovascular disease. The companies w...